Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07491367 · ClinicalTrials.gov registry record · Phase 4
Pilot Exploration of Platelet Characterization of Platelet Rich Plasma Created by Two Different Systems
A Phase 4 study, sponsored by University of California, San Francisco.
- Not yet
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT07491367 is a Phase 4 study that has not yet begun recruiting, run by University of California, San Francisco. The registered enrollment target is 20 participants.
The verdict
NCT07491367, a Phase 4 study, has not yet begun recruiting, sponsored by University of California, San Francisco.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
The investigators would like to study the differences in the quality of Platelet Rich Plasma (PRP) between two different machines in those with knee osteoarthritis. Knee osteoarthritis means your cartilage has been worn down, and it affects your knee joint. Both machines, the APEX Biologix XCELL PRP System and the Emcyte PurePRP Supraphysiologic Concentrating System, are FDA approved, commercially available, and makes PRP. The investigators will check if the platelets in the PRP have different amounts or work differently. The investigators will also assess participants symptoms after the injection and compare the two different preparation systems.
Interventions
- BIOLOGICAL Platelet Rich Plasma
- DEVICE Emcyte PurePRP Supraphysiologic Concentrating System
- DEVICE APEX Biologix XCELL PRP System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2028-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07491367
The ClinicalTrials.gov registry entry for NCT07491367 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Platelet Rich Plasma is the first listed.
NCT07491367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07491367 about?
NCT07491367 is a clinical study titled "Pilot Exploration of Platelet Characterization of Platelet Rich Plasma Created by Two Different Systems". The investigators would like to study the differences in the quality of Platelet Rich Plasma (PRP) between two different machines in those with knee osteoarthritis. Knee osteoarthritis means your cartilage has been worn down, and it affects your knee joint. Both machines, the APEX Biologix XCELL PRP...
What is the current status of trial NCT07491367?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2026-07-01. Estimated completion is 2028-09.
What interventions are being tested in trial NCT07491367?
The interventions under investigation include: Platelet Rich Plasma (BIOLOGICAL), Emcyte PurePRP Supraphysiologic Concentrating System (DEVICE), APEX Biologix XCELL PRP System (DEVICE).
Who is sponsoring clinical trial NCT07491367?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.